Autres langues Hemogenyx Pharmaceuticals Plc

Actions

SILF

GB00BYX3WZ24

Temps Différé London S.E. Autres places de cotation 13:14:24 29/04/2024			Varia. 5j.	Varia. 1 janv.
1,603 ^GBX	-2,85%		-0,74%	-30,30%

25/04	Hemogenyx Pharmaceuticals Plc publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
29/02	Hemogenyx Pharmaceuticals lève des fonds pour un traitement contre la leucémie	AN

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	25/04
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Hemogenyx Pharmaceuticals discusses successful Ã‚£3.5M capital raise as it advances HEMO-CAR-T program	12/03
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	29/02
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	29/02
Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform	20/02
Hemogenyx Pharmaceuticals PLC Announces CBR Brain Delivery	19/02
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	16/02
Hemogenyx shares rise on potential for CBR to treat brain diseases	16/02
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	16/02
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	14/02
Hemogenyx says CBR can be used intranasally to treat viral infections	14/02
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	09/02
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	09/02
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	09/02
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	02/02
Hemogenyx hails US patent application progress	02/02
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	02/02
Hemogenyx Pharmaceuticals plc - Submission of Complete Response to Clinical Hold for HEMO-CAR-T IND	17/01
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Hemogenyx Pharmaceuticals Plc

Actions

SILF

GB00BYX3WZ24

Autres langues

Filtres